Anagrelide for Essential Thrombocythemia
Anagrelide (an ag' gre lide) hydrochloride (Agrylin - Roberts), a quinazolin derivative, has been approved by the FDA for oral treatment of essential thrombocythemia. Patients with this uncommon myeloproliferative disorder have an increased number of circulating platelets and are at risk for both thrombosis and hemorrhage....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Anagrelide for Essential Thrombocythemia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1016
Article Code: 1016c
Date: December 19, 1997
Volume: 39
Page: 120
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1016
Article Code: 1016c
Date: December 19, 1997
Volume: 39
Page: 120
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)